Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation

被引：74
作者：
Chapuy, Claudia I. [1 ,5 ]
Kaufman, Richard M. [2 ]
Alyea, Edwin P. [4 ]
Connors, Jean M. [3 ]
机构：
[1] St Elizabeths Med Ctr, Dana Farber Canc Inst, Boston, MA USA
[2] Brigham & Womens Hosp, Dept Pathol, Blood Bank, 75 Francis St, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Div Hematol, 75 Francis St, Boston, MA 02115 USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Univ Med Ctr, Dept Hematol & Oncol, Gottingen, Germany
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 19期
关键词：
BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; PERIPHERAL-BLOOD; MULTIPLE-MYELOMA; HPC TRANSPLANTATION; APLASIA; RITUXIMAB; ERYTHROPOIETIN; MONOTHERAPY; ANTIBODY;
D O I：
10.1056/NEJMoa1807438
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Daratumumab, a human IgG1 monoclonal antibody targeting CD38, is used to treat multiple myeloma. We describe successful treatment with daratumumab in a case of treatment-refractory pure red-cell aplasia after ABO-mismatched allogeneic stem-cell transplantation. The patient was a 72-year-old man with the myelodysplastic syndrome who received a transplant from an HLA-matched, unrelated donor with a major ABO incompatibility (blood group A in the donor and blood group O in the recipient). The patient had persistent circulating anti-A antibodies and no red-cell recovery 200 days after transplantation. Standard treatments had no effect. Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions.
引用
收藏
页码：1846 / 1850
页数：5
相关论文
共 31 条
  • [1] Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation
    Bolan, CD
    Leitman, SF
    Griffith, LM
    Wesley, RA
    Procter, JL
    Stroncek, DF
    Barrett, AJ
    Childs, RW
    [J]. BLOOD, 2001, 98 (06) : 1687 - 1694
  • [2] Clinical Guide to ASO-Incompatible Allogeneic Stem Cell Transplantation
    Booth, Garrett S.
    Gehrie, Eric A.
    Bolan, Charles D.
    Savani, Bipin N.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (08) : 1152 - 1158
  • [3] Resolving the daratumumab interference with blood compatibility testing
    Chapuy, Claudia I.
    Nicholson, Rachel T.
    Aguad, Maria D.
    Chapuy, Bjoern
    Laubach, Jacob P.
    Richardson, Paul G.
    Doshi, Parul
    Kaufman, Richard M.
    [J]. TRANSFUSION, 2015, 55 (06) : 1545 - 1554
  • [4] Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
    de Weers, Michel
    Tai, Yu-Tzu
    van der Veer, Michael S.
    Bakker, Joost M.
    Vink, Tom
    Jacobs, Danielle C. H.
    Oomen, Lukas A.
    Peipp, Matthias
    Valerius, Thomas
    Slootstra, Jerry W.
    Mutis, Tuna
    Bleeker, Wim K.
    Anderson, Kenneth C.
    Lokhorst, Henk M.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 186 (03) : 1840 - 1848
  • [5] The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation
    Erker, CG
    Steins, MB
    Fischer, RJ
    Kienast, J
    Berdel, WE
    Sibrowski, W
    Cassens, U
    [J]. TRANSFUSION, 2005, 45 (08) : 1382 - 1390
  • [6] Pure red cell aplasia with the onset of graft versus host disease
    Grigg, AP
    Juneja, SK
    [J]. BONE MARROW TRANSPLANTATION, 2003, 32 (11) : 1099 - 1101
  • [7] Helbig Grzegorz, 2005, Haematologica, V90 Suppl, pECR33
  • [8] HEYLL A, 1991, BLOOD, V77, P906
  • [9] Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program
    Kimura, Fumihiko
    Sato, Ken
    Kobayashi, Shinichi
    Ikeda, Takashi
    Sao, Hiroshi
    Okamoto, Shinichiro
    Miyamura, Koichi
    Mori, Shin-ichiro
    Akiyama, Hideki
    Hirokawa, Makoto
    Ohto, Hitoshi
    Ashida, Hiroshi
    Motoyoshi, Kazuo
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (11): : 1686 - 1693
  • [10] Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation
    Lee, JH
    Lee, KH
    Kim, S
    Lee, JS
    Kim, SH
    Kwon, SW
    Kim, WK
    [J]. BONE MARROW TRANSPLANTATION, 2000, 25 (02) : 179 - 184
1234